

Bernard Bonnotte

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1066857/bernard-bonnotte-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79
papers

3,999
citations

31
h-index

63
g-index

95
ext. papers

4,906
ext. citations

6.3
avg, IF

4.77
L-index

#	Paper	IF	Citations
79	T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients.. <i>European Journal of Internal Medicine</i> , 2022 ,	3.9	1
78	New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2905	5.1	1
77	Emerging Therapies in Immune Thrombocytopenia. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	7
76	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 339-346	5.3	8
75	Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments. <i>HemaSphere</i> , 2021 , 5, e574	0.3	8
74	Myocardial infarction during giant cell arteritis: A cohort study. <i>European Journal of Internal Medicine</i> , 2021 , 89, 30-38	3.9	2
73	Ustekinumab For the Treatment of Giant Cell Arteritis: Comment on the Article by Matza et al. <i>Arthritis Care and Research</i> , 2021 , 73, 1058-1059	4.7	3
72	Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. <i>Clinical and Translational Immunology</i> , 2021 , 10, e1332	6.8	6
71	Localised Versus Systemic Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry. <i>Rheumatology</i> , 2021 ,	3.9	2
70	Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
69	Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 173, 179-187	8	44
68	Impact of the COVID-19 lockdown on the management and control of patients with GCA. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	4
67	Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. <i>Autoimmunity Reviews</i> , 2018 , 17, 391-398	13.6	50
66	Biological treatments in giant cell arteritis & Takayasu arteritis. <i>European Journal of Internal Medicine</i> , 2018 , 50, 12-19	3.9	22
65	Venous thromboembolic events during warm autoimmune hemolytic anemia. <i>PLoS ONE</i> , 2018 , 13, e0207218	3.7	29
64	Giant Cell Arteritis-related Stroke: A Retrospective Multicenter Case-control Study. <i>Journal of Rheumatology</i> , 2017 , 44, 297-303	4.1	47
63	Pathogenesis of immune thrombocytopenia. <i>Autoimmunity Reviews</i> , 2017 , 16, 620-632	13.6	148

62	Recent advances in our understanding of giant cell arteritis pathogenesis. <i>Autoimmunity Reviews</i> , 2017 , 16, 833-844	13.6	95
61	B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia. <i>Journal of Autoimmunity</i> , 2017 , 77, 89-95	15.5	19
60	Involvement and prognosis value of CD8(+) T cells in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2016 , 72, 73-83	15.5	37
59	Endovascular stent placement for chronic post-thrombotic symptomatic ilio-femoral venous obstructive lesions: a single-center study of safety, efficacy and quality-of-life improvement. <i>Quantitative Imaging in Medicine and Surgery</i> , 2016 , 6, 342-352	3.6	16
58	A New Prognosis Score to Predict Mortality After Acute Pneumonia in Very Elderly Patients. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 1123-1128	5.9	6
57	Stroke associated with giant cell arteritis: a population-based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 216-21	5.5	67
56	Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. <i>Journal of Autoimmunity</i> , 2015 , 62, 22-30	15.5	31
55	Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. <i>Rheumatology</i> , 2015 , 54, 940-9	3.9	44
54	Good syndrome: an adult-onset immunodeficiency remarkable for its high incidence of invasive infections and autoimmune complications. <i>Clinical Infectious Diseases</i> , 2015 , 61, e13-9	11.6	56
53	Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3-positive CD8+ T lymphocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 135, 1614-24.e4	11.5	13
52	How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network. <i>Blood</i> , 2015 , 126, 456-456	2.2	3
51	Splenic and Circulating Human T Follicular Helper Cell Regulation By B Cell Depleting Therapy during Immune Thrombocytopenia. <i>Blood</i> , 2015 , 126, 8-8	2.2	
50	Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. <i>Cancer Research</i> , 2014 , 74, 104-18	10.1	247
49	PIAS1 and STAT-3 impair the tumoricidal potential of IFN- β -stimulated mouse dendritic cells generated with IL-15. <i>European Journal of Immunology</i> , 2014 , 44, 2489-2499	6.1	3
48	Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , 2014 , 371, 1771-80	59.2	573
47	Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia. <i>European Journal of Internal Medicine</i> , 2014 , 25, 837-42	3.9	13
46	Is TNF- β really involved in giant cell arteritis pathogenesis?. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e1	2.4	8
45	Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. <i>Blood</i> , 2014 , 124, 2858-66	2.2	44

44	Does tocilizumab indeed reduce the frequency of Th17 cells? Comment on the article by Thiolat et al. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2639-40	9.5	1
43	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. <i>Presse Medicale</i> , 2013 , 42, 1317-30	2.2	49
42	Treg cells in giant cell arteritis: might they be another target for adjuvant treatment? Comment on the article by Samson et al. Reply. <i>Arthritis and Rheumatism</i> , 2013 , 65, 289-90		1
41	Inhibition of the HER2 pathway by n-3 polyunsaturated fatty acids prevents breast cancer in fat-1 transgenic mice. <i>Journal of Lipid Research</i> , 2013 , 54, 3453-63	6.3	29
40	Reply: To PMID 22833233. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1134-5		1
39	Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigole et al. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, e3	2.4	2
38	Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. <i>American Journal of Hematology</i> , 2013 , 88, 858-61	7.1	22
37	Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. <i>Blood</i> , 2013 , 122, 2477-86	2.2	30
36	Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature. <i>Medicine (United States)</i> , 2013 , 92, 69-81	1.8	31
35	A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. <i>Blood</i> , 2012 , 120, 4938-44	2.2	50
34	Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3788-98		115
33	Myeloid-derived suppressor cells from tumor-bearing mice impair TGF- β -induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. <i>Journal of Leukocyte Biology</i> , 2012 , 92, 987-97 ^{6.5}		60
32	Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2499-503		247
31	LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2012 , 51, 1906-15	3.9	37
30	Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells. <i>OncolImmunology</i> , 2012 , 1, 566-568	7.2	3
29	Alpha-interferon secreting blastic plasmacytoid dendritic cells neoplasm: a case report with histological, molecular genetics and long-term tumor cells culture studies. <i>American Journal of Dermatopathology</i> , 2012 , 34, 626-31	0.9	8
28	Cost Effectiveness of Rituximab Given At Fixed Dose (1000 mg on days 1 and 15) Compared to the Standard Regimen in adult's Immune Thrombocytopenia.. <i>Blood</i> , 2012 , 120, 2157-2157	2.2	
27	Failure of Rituximab in Immune Thrombocytopenia Is Associated with the Activation of Splenic CD8 T Cells. <i>Blood</i> , 2012 , 120, 623-623	2.2	1

26	Dendritic cell-tumor cell hybrids and immunotherapy: what's next?. <i>Cytotherapy</i> , 2011 , 13, 774-85	4.8	15
25	Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN- γ -dependent mechanism. <i>Journal of Immunology</i> , 2011 , 187, 6310-7	5.3	24
24	Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. <i>Blood</i> , 2011 , 118, 4394-400	2.2	82
23	Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. <i>Blood</i> , 2011 , 117, 1555-64	2.2	16
22	Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience. <i>Haematologica</i> , 2011 , 96, 1276-83	6.6	32
21	Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. <i>British Journal of Haematology</i> , 2011 , 155, 498-508	4.5	98
20	Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. <i>Joint Bone Spine</i> , 2011 , 78, 241-5	2.9	28
19	Cytotoxic dendritic cells generated from cancer patients. <i>Journal of Immunology</i> , 2011 , 187, 2775-82	5.3	18
18	Stratégie diagnostique devant la découverte d'une hypogammaglobulinémie en rhumatologie. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2011 , 78, 122-127	0.1	2
17	The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. <i>Clinical and Developmental Immunology</i> , 2011 , 2011, 430394		62
16	Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. <i>Journal of Immunology</i> , 2010 , 184, 1876-84	5.3	43
15	Killer dendritic cells and their potential for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 1-11	7.4	37
14	Evaluation of the Prognostic Value of CD45RO+ and FOXP3+ Cells of the Micro-Environment In Classical Hodgkin Lymphomas Using Tissue Micro Array. <i>Blood</i> , 2010 , 116, 2687-2687	2.2	
13	Liver X receptor-mediated induction of cholesteryl ester transfer protein expression is selectively impaired in inflammatory macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 1923-9	2.4	20
12	Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. <i>American Journal of Hematology</i> , 2009 , 84, 153-7	7.1	77
11	Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1329-38	11.6	143
10	The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. <i>Experimental Cell Research</i> , 2007 , 313, 2345-55	4.2	32
9	Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006 , 11, 1513-24	5.4	34

8	CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. <i>European Journal of Immunology</i> , 2004 , 34, 336-44	6.1	758
7	Intravascular malignant lymphomatosis diagnosed on a muscular biopsy: a case report. <i>European Journal of Internal Medicine</i> , 2004 , 15, 190-192	3.9	2
6	Freshly isolated bone marrow cells induce death of various carcinoma cell lines. <i>International Journal of Cancer</i> , 2003 , 107, 747-56	7.5	16
5	A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. <i>Nature Medicine</i> , 2003 , 9, 1215-9	50.5	63
4	An atypical caspase-independent death pathway for an immunogenic cancer cell line. <i>Oncogene</i> , 2002 , 21, 6091-100	9.2	13
3	Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. <i>International Journal of Cancer</i> , 2000 , 86, 827-34	7.5	18
2	FAS(CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection. <i>International Journal of Cancer</i> , 1999 , 82, 359-67	7.5	3
1	Efficacy of colchicine alone or in combination with vinca alkaloids in severe corticoid-resistant thrombocytopenic purpura: six cases. <i>American Journal of Medicine</i> , 1999 , 107, 645-6	2.4	2